References
- Center for Disease Control and Prevention (CDC). Opioid Overdose. Understanding the Epidemic [Cited 2020 Dec 3]. Available from: https://www.cdc.gov/drugoverdose/epidemic/index.html.
- Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999-2018 on CDC WONDER Online Database, released January, 2020 [Cited 2020 Dec 3]. Available from: https://www.drugabuse.gov/drug-topics/trends-statistics/overdose-death-rates.
- Wakeman SE, Green TC, Rich J. An overdose surge will compound the COVID-19 pandemic if urgent action is not taken. Nat Med. 2020 Jun;26(6):819–820.
- Becker WC, Fiellin DA. When epidemics collide: coronavirus disease 2019 (COVID-19) and the opioid crisis. Ann Intern Med. 2020;173(1):59–60.
- Centers for Disease Control and Prevention (CDC). Health advisory (CDCHAN-00438). Increase in Fatal Drug Overdoses Across the United States Driven by Synthetic Opioids Before and During the COVID-19 Pandemic. 2020 [Cited 2021 Jan 5]. Available from: https://emergency.cdc.gov/han/2020/han00438.asp?ACSTrackingID=USCDC_511-DM44961&ACSTrackingLabel=HAN%20438%20-%20General%20Public&deliveryName=USCDC_511-DM44961.
- The Opioid Response Network. The opioid epidemic and COVID-19: how social determinants of health create differential impacts. 2020 [Cited 2021 Jan 5]. Available from: https://opioidresponsenetwork.org/documents/SDH_OUD-COVID-19.pdf
- American Medical Association (AMA). Issue brief: reports of increases in opioid-related overdose during COVID pandemic. 2020 [Cited 2020 Dec 3]. Available from: https://www.ama-assn.org/system/files/2020-11/issue-brief-increases-in-opioid-related-overdose.pdf.
- Slavova S, Rock P, Bush HM, et al. Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol Depend. 2020;214:108176.
- Society of Actuaries. Economic Impact of Non-Medical Opioid Use in the United States [Cited 2020 Dec 3]. Available from: https://www.soa.org/globalassets/assets/files/resources/research-report/2019/econ-impact-non-medical-opioid-use.pdf.
- Florence C, Luo F, Rice K. The economic burden of opioid use disorder & fatal opioid overdose in the United States, 2017. Drug Alcohol Depend. 2020. In Press. DOI:10.1016/j.drugalcdep.2020.108350
- Substance Abuse and Mental Health Services Administration (SAMHSA). Key substance use and mental health indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54). 2019 [Cited 2020 Dec 3]. Available from: www.samhsa.gov/data/.
- Ruetsch C, Tkacz J, Nadipelli VR, et al. Heterogeneity of nonadherent buprenorphine patients: subgroup characteristics and outcomes. Am J Manag Care. 2017 Jun 1;23(6):e172–e179.
- Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Network Open. 2020;3(2):e1920622–e1920622. .
- Ronquest NA, Willson TM, Montejano LB, et al. Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder. Subst Abuse Rehabil. 2018;9:59–78.
- Lynch FL, McCarty D, Mertens J, et al. Costs of care for persons with opioid dependence in commercial integrated health systems. Addict Sci Clin Pract. 2014 [2014 08 14];9(1):16. .
- Velez FF, Colman S, Kauffman L, et al. Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic. Expert Review of Pharmacoeconomics & Outcomes Research. 2020.
- Johnson K, Hills H, Jifeng M, et al. Treatment for opioid use disorder in the Florida medicaid population: using a cascade of care model to evaluate quality. Am J Drug Alcohol Abuse. 2020;1–9. DOI:10.1080/00952990.2020.1824236
- Centers for Disease Control and Prevention (CDC). Opioid Overdose: Assessing and Addressing Opioid Use Disorder (OUD). 2018 [Cited 2021 Jan 5]. Available from: https://www.cdc.gov/drugoverdose/training/oud/accessible/index.html
- Madras B, Ahmad NJ, Wen J, et al., and the Prevention, Treatment, and Recovery Working Group of the Action Collaborative on Countering the U.S. Opioid Epidemic. Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers Within the Treatment System 2020 [Cited 2020 Dec 3]. Available from: https://nam.edu/improving-access-to-evidence-based-medical-treatment-for-opioid-use-disorder-strategies-to-address-key-barriers-within-the-treatment-system/.
- Hser Y-I, Saxon AJ, Huang D, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79–87.
- NIDA. 2020, June 1. Community Reinforcement Approach Plus Vouchers (Alcohol, Cocaine, Opioids)[Cited 2020 Dec 3]. Available from: https://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-based-guide-third-edition/evidence-based-approaches-to-drug-addiction-treatment/behavioral-therapies/community-reinforcement-approach-vouchers.
- McLellan AT, Arndt IO, Metzger DS, et al. The effects of psychosocial services in substance abuse treatment. JAMA. 1993;269(15):1953–1959.
- Marsch LA, Dallery J. Advances in the psychosocial treatment of addiction: the role of technology in the delivery of evidence-based psychosocial treatment. Psychiatr Clin North Am. 2012;35(2):481–493.
- Pear Therapeutics Inc. reSET-O - Clinician Instructions for Use. 2019 [Cited 2020 Aug 17]. Available from: https://peartherapeutics.com/wp-content/uploads/2019/08/PEAR-MKT-025-reSET-O-Clin-Brief-Sum_Dec2019.pdf.
- Vilardaga R, Fisher T, Sabo PL, et al. (2020). Review of popularity and quality standards of opioid-related smartphone apps. Current Addiction Reports. DOI: 10.1007/s40429-020-00344-6
- Tkacz J, Volpicelli J, Un H, et al. Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients. J Subst Abuse Treat. 2014;46(4):456–462.
- Maricich YA, Xiong X, Gerwien R, et al. Real-world evidence for a prescription digital therapeutic to treat opioid use disorder. Curr Med Res Opin. 2020. DOI:10.1080/03007995.2020.1846023
- Wang W, Gellings Lowe N, Jalali A, et al. Economic modeling of reSET-O, a prescription digital therapeutic for patients with opioid use disorder. J Med Econ. 2020. DOI:10.1080/13696998.2020.1858581
- Christensen DR, Landes RD, Jackson L, et al. Adding an internet-delivered treatment to an efficacious treatment package for opioid dependence. J Consult Clin Psychol. 2014;82(6):964–972. .
- Maricich YA, Bickel WK, Marsch LA, et al. Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for treatment of opioid use disorder. Curr Med Res Opin. 2020. DOI:10.1080/03007995.2020.1846022
- Pyne JM, Tripathi S, French M, et al. Longitudinal association of preference-weighted health-related quality of life measures and substance use disorder outcomes. Addiction. 2011;106(3):507–515.
- Fryback DG, Dunham NC, Palta M, et al. U.S. norms for six generic health-related quality-of-life indexes from the national health measurement study. Med Care. 2007;45(12):1162–1170. .
- Walters SJ, Brazier JE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes. 2003;1(1):4.
- IBM Micromedex RED BOOK [Internet]. IBM Watson Health™, an IBM Company; c2017. [cited 2019 Feb 20]. Available from: https://www.ibm.com/us-en/marketplace/micromedex-red-book.
- Sindelar JL, Olmstead TA, Peirce JM. Cost-effectiveness of prize-based contingency management in methadone maintenance treatment programs. Addiction. 2007;102(9):1463–1471.
- Petry NM, DePhilippis D, Rash CJ, et al. Nationwide dissemination of contingency management: the veterans administration initiative. Am J Addict. 2014;23(3):205–210.
- Institute for Clinical and Economic Review (ICER). Extended-Release Opioid Agonists and Antagonist Medications for Addiction Treatment (MAT) in Patients with Opioid Use Disorder: Effectiveness and Value. 2018 [Cited 2020 Dec 3]. Available from: https://icer-review.org/wp-content/uploads/2018/04/ICER_Opioid_Use_Disorder_Draft_Evidence_Report_090718-1.pdf.
- Bickel WK, Marsch LA, Buchhalter AR, et al. Computerized behavior therapy for opioid-dependent outpatients: a randomized controlled trial. Exp Clin Psychopharmacol. 2008;16(2):132–143.
- Proctor R, Taylor MP, Quinn M, et al. Alarming rate of substance use in motor vehicle collisions at an appalachian trauma center. Cureus. 2020 December 03;12(12):e11863.
- Cahill CM, Walwyn W, Taylor AMW, et al. Allostatic mechanisms of opioid tolerance beyond desensitization and downregulation. Trends Pharmacol Sci. 2016 Nov;37(11):963–976.
- Montandon G, Slutsky AS. Solving the opioid crisis: respiratory depression by opioids as critical end point. Chest. 2019 Oct;156(4):653–658.
- Morse ED. Addiction is a chronic medical illness. N C Med J. 2018 May-Jun;79(3):163–165. . PMID: 29735618
- Chisholm D, Evans DB. Economic evaluation in health: saving money or improving care? J Med Econ. 2007;10(3):325–337.
- Sulley S, Ndanga M. Inpatient opioid use disorder and social determinants of health: a nationwide analysis of the national inpatient sample (2012-2014 and 2016-2017). Cureus. 2020 November 03;12(11):e11311.
- Wittenberg E, Bray JW, Aden B, et al. Measuring benefits of opioid misuse treatment for economic evaluation: health-related quality of life of opioid-dependent individuals and their spouses as assessed by a sample of the US population. Addiction. 2016;111(4):675–684.